STOCKHOLM, Dec. 6, 2023
/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a
pharmaceutical company focused on developing innovative treatments
for cancer in areas of high unmet medical need, announces
that the company will present at the Carlsquare Equity Research
Investor Day, today December 6,
2023.
CEO Jens Lindberg will present at
14.30 CET, with focus on the latest developments and the company's
future plans. This will include, among other things, the company's
rights issue and how it aims to ensure the highest possible speed
and momentum in the development program for fostrox with the aim of
starting a pivotal phase 2b study in
2024.
The presentation is live broadcasted and can be followed at
the event page;
Carlsquare | Investor Day - Life Science - YouTube
For additional information, please contact
Magnus Christensen, CFO, Medivir
AB
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
Medivir in brief
Medivir develops innovative drugs with a focus on cancer where
the unmet medical needs are high. The drug candidates are directed
toward indication areas where available therapies are limited or
missing and there are great opportunities to offer significant
improvements to patients. Medivir is focusing on the development of
fostroxacitabine bralpamide (fostrox), a pro-drug designed to
selectively treat liver cancer cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's
business model, and the drug development is conducted either by
Medivir or in partnership. Birinapant, a SMAC mimetic, is
exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be
developed in combination with IGM-antibodies for the treatment of
solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq
Stockholm's Small Cap list. www.medivir.com.
The following files are available for download:
|
https://mb.cision.com/Main/652/3888974/2476730.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/medivir-to-present-at-the-carlsquare-equity-research-investor-day-302007187.html
SOURCE Medivir